Abstract
Many postmenopausal women with advanced or metastatic breast cancer (BC) receive nonsteroidal aromatase inhibitors (NSAIs). Virtually all of them experience progression, but may still gain benefit from a different endocrine or targeted agent. We indirectly compare the results of trials on endocrine or targeted treatment in HR+/HER2- mBC patients who progressed after a prior NSAI therapy. Although with the limitations of any indirect comparison, evidence suggests that only the combination of everolimus and exemestane is associated with a prolonged progression-free survival and a more evident clinical benefit than its comparators. We speculate that prior NSAI therapy can 'per se' individuate patients eligible to everolimus. More robust data from head-to-head trials will provide more grounded evidence on this issue.
Original language | English |
---|---|
Pages (from-to) | 975-981 |
Number of pages | 7 |
Journal | Future Oncology |
Volume | 11 |
Issue number | 6 |
DOIs | |
Publication status | Published - Mar 1 2015 |
Keywords
- aromatase inhibitors
- breast cancer
- disease progression
- endocrine treatment
- second-line therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)